Cumberland Pharmaceuticals (CPIX) Capital Expenditures (2010 - 2025)

Cumberland Pharmaceuticals has disclosed Capital Expenditures across 16 years of filings, most recently posting -$1.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at -$1.0, down 100.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $50273.0 (down 30.63% YoY), and the FY2025 annual result was $97903.0, up 47.31% from the prior year.
• Capital Expenditures came in at -$1.0 for Q4 2025 at Cumberland Pharmaceuticals, down from $23788.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $137255.0 in Q2 2022 to a low of -$153528.0 in Q4 2022.
• The 5-year median for Capital Expenditures is $26736.0 (2022), against an average of $32565.6.
• Peak annual rise in Capital Expenditures reached 810.6% in 2022, while the deepest fall reached 1797.0% in 2022.
• Cumberland Pharmaceuticals' Capital Expenditures stood at $9047.0 in 2021, then tumbled by 1797.0% to -$153528.0 in 2022, then soared by 131.7% to $48673.0 in 2023, then tumbled by 95.31% to $2283.0 in 2024, then tumbled by 100.04% to -$1.0 in 2025.
• The last three Capital Expenditures figures came in at -$1.0 (Q4 2025), $23788.0 (Q3 2025), and $26486.0 (Q2 2025), per Business Quant data.